#Sweden #Lund #Hansa Biopharma #imlifidase #Transplant Surgeons

Hansa Biopharma Hosts Virtual Event with Esteemed Transplant Surgeons

Hansa Biopharma AB, the innovative biopharmaceutical company, is set to host a remarkable virtual event featuring two eminent transplant surgeons, Professor Robert Montgomery and Professor Matthew Cooper. Scheduled for November 12, 2025, at 9 AM EST / 3 PM CET, the event aims to shed light on the medical journeys of highly sensitized patients who are on the waiting list for kidney transplants. This session promises to be an important discussion about the clinical relevance of the topline results from the US Phase 3 clinical trial, known as the ConfIdeS study.

Event Schedule and Key Participants

The virtual event will commence with an introductory speech from Renée Aguiar-Lucander, CEO of Hansa Biopharma. Following that, Richard Philipson, the Chief Medical Officer of Hansa, will present the topline results derived from the ConfIdeS trial. The conversation will then be moderated by Philipson as he delves into contemporary challenges faced by highly sensitized patients, who often endure lengthy waiting times on transplant lists due to their unique medical needs and profiles.

Joining Professor Montgomery and Professor Cooper for this crucial dialogue will provide invaluable insights into how the results of the ConfIdeS study could influence current clinical practices and improve standards of care in the transplant community across the United States.

About the Keynote Speakers

Dr. Robert Montgomery is the Chair of the Surgery Department and the director of the NYU Langone Transplant Institute. As a pioneer in desensitization techniques, Dr. Montgomery's career has been marked by groundbreaking innovations, including the development of the first ‘domino paired donation.’ His personal experience as a heart transplant recipient adds depth to his expertise in transplantation.

Dr. Matthew Cooper, Chief of Transplantation and Director of Solid Organ Transplant at the Medical College of Wisconsin, is renowned for his transformative contributions to kidney transplantation. A board member of both the American Society of Transplantation and the National Kidney Foundation, he has authored a plethora of publications in this field, positioning him as a thought leader in transplantation.

Understanding Highly Sensitized Patients

Highly sensitized patients, characterized by pre-formed donor specific antibodies (DSAs), face significant hurdles in obtaining compatible organs for transplantation. These antibodies can instigate severe tissue damage or transplant rejection, leading to extended waiting times for suitable donors. In the U.S. and Europe, these patients comprise about 10-15% of those waiting for transplants. The urgency for new therapeutic strategies in addressing their unique challenges underscores the importance of events like the one hosted by Hansa Biopharma.

Imlifidase: A Potential Game-Changer

The focus of much of the discussion will likely be on imlifidase, Hansa's pioneering antibody-cleaving enzyme. This groundbreaking treatment offers hope for highly sensitized patients by rapidly inactivating harmful antibodies. Imlifidase received conditional marketing approval in Europe under the name IDEFIRIX and has been integral in the desensitization of adult kidney transplant patients who have tested positively for crossmatching.

The therapeutic potential of imlifidase lies in its ability to create a crucial window for transplantation to occur by preparing patients to safely receive donor organs without the immediate risk of rejection.

Conclusion

This virtual event promises to be a pivotal moment for both the clinical community and patients awaiting kidney transplants. By bringing together leading experts and focusing on their clinical experiences and research on Imlifidase, Hansa Biopharma aims to take significant steps toward better understanding and improving treatment options for some of the most vulnerable patients in the transplant community. Join this compelling discussion by registering for the event today and be part of the transformative dialogue that aims to change lives.

For further details, visit the official event page here.